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ympathetic Dysfunction in Type 1 Diabetes
ssociation With Impaired Myocardial
lood Flow Reserve and Diastolic Dysfunction
odica Pop-Busui, MD,*§ Ian Kirkwood, MBBS,* Helena Schmid, MD,* Victor Marinescu, BS,*
ustin Schroeder, BS,* Dennis Larkin, BS,* Elina Yamada, MD,† David M. Raffel, PHD,‡
artin J. Stevens, MD*
nn Arbor, Michigan; and Toledo, Ohio
OBJECTIVES This study was designed to explore the relationships of early diabetic microangiopathy to
alterations of cardiac sympathetic tone and myocardial blood flow (MBF) regulation in
subjects with stable type 1 diabetes.
BACKGROUND In diabetes, augmented cardiac sympathetic tone and abnormal MBF regulation may
predispose to myocardial injury and enhanced cardiac risk.
METHODS Subject groups comprised healthy controls (C) (n  10), healthy diabetic subjects (DC) (n 
12), and diabetic subjects with very early diabetic microangiopathy (DMA) (n  16).
[11C]meta-hydroxyephedrine ([11C]HED) and positron emission tomography (PET) were
used to explore left ventricular (LV) sympathetic integrity and [13N]ammonia-PET to assess
MBF regulation in response to cold pressor testing (CPT) and adenosine infusion.
RESULTS Deficits of LV [11C]HED retention were extensive and global in the DMA subjects (36 
31% vs. 1 1% in DC subjects; p 0.01) despite preserved autonomic reflex tests. On CPT,
plasma norepinephrine excursions were two-fold greater than in C and DC subjects (p 
0.05), and basal LV blood flow decreased (12%, p  0.05) in DMA but not in C or DC
subjects (45% and 51%, respectively). On adenosine infusion, compared with C subjects,
MBF reserve decreased by 45% (p  0.05) in DMA subjects. Diastolic dysfunction was
detected by two-dimensional echocardiography in 5 of 8 and 0 of 8 consecutively tested
DMA and DC subjects, respectively.
CONCLUSIONS Augmented cardiac sympathetic tone and responsiveness and impaired myocardial perfusion
may contribute to myocardial injury in diabetes. (J Am Coll Cardiol 2004;44:2368–74)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.033© 2004 by the American College of Cardiology Foundation
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rn diabetes, the etiology of enhanced cardiac risk is thought
o reflect the detrimental consequences of myocardial isch-
mia, oxidative stress, and alterations in myocardial sub-
trate metabolism (1–3). Additionally, a putative diabetic
ardiomyopathy comprising myocardial interstitial and
erivascular fibrosis (1) and apoptosis (2) has been identified
n patients without coronary artery disease and linked to the
evelopment of impaired left ventricular (LV) function (3).
ndeed, alterations of diastolic (3–5) and systolic (6) func-
ion are widely reported in healthy diabetic subjects and
ften predate the development of other chronic diabetic
omplications.
Although the etiology of myocardial injury and dysfunc-
ion in diabetes uncomplicated by the presence of coronary
From the Divisions of *Endocrinology and Metabolism, †Cardiology, and ‡Nu-
lear Medicine, Department of Internal Medicine, University of Michigan, Ann
rbor, Michigan; and the §Division of Endocrinology and Metabolism, Department
f Internal Medicine, Medical College of Ohio, Toledo, Ohio. This work was
upported in part by grants from the Juvenile Diabetes Research Foundation (to Dr.
tevens), the National Institutes of Health R01-DK52391 (to Dr. Stevens), a
eterans Administration Career Development Award (to Dr. Stevens), American
iabetes Association (to Dr. Stevens), and a University of Michigan General Clinical
esearch Center (GCRC) grant (to Dr. Stevens). The first two authors contributed
qually to these studies.i
Manuscript received November 24, 2003; revised manuscript received July 2, 2004,
ccepted September 14, 2004.ascular disease is not well understood, alterations of cardiac
ympathetic innervation, tone, and responsiveness (7,8),
oupled with abnormal myocardial blood flow (MBF) reg-
lation (9–14), have emerged as potential contributing
actors. In experimental diabetes, the initial development of
ardiovascular autonomic neuropathy (CAN) is character-
zed by early augmentation of sympathetic tone (15,16),
hich may contribute to myocardial injury (15,17). There-
ore, in diabetes, increased cardiac sympathetic nervous
ystem activity and elevated cardiac synaptic norepinephrine
15,18) or enhanced myocardial norepinephrine sensitivity
ay provide a mechanistic explanation for myocardial injury
redisposing to the development of impaired LV function
nd enhanced cardiac risk. We therefore wished to explore
he hypothesis that early preclinical diabetic microangiopa-
hy is complicated by abnormalities in cardiac sympathetic
ervous system innervation and blood flow regulation,
hich could ultimately predispose to the development of
ardiomyopathy.
ETHODS
atient population. Subjects with type 1 diabetes were
ecruited from the Michigan Diabetes Research and Train-
ng Center. Subject groups comprised healthy nondiabetic
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December 21, 2004:2368–74 Sympathetic Dysfunction in Diabetesontrols (C) (n  10); healthy diabetic control subjects
DC) (n  12); and diabetic subjects with very early
icroangiopathy (DMA) (n  16), defined by the pres-
nce of early nonproliferative diabetic retinopathy (n  14)
r early microalbuminuria (n  2) and/or early peripheral
europathy (n  10). All subjects were matched for age and
iabetes duration and were free from dyslipidemia and
acrovascular complications (Table 1).
All of the DMA subjects had undergone negative
cintigraphic cardiac stress testing within one year preceding
his study. No subjects had a history of hypertension or were
aking vasoactive medications, lipid-lowering agents, or
edications known to alter sympathetic tone. Written
nformed consent was obtained and the study protocol was
pproved by the institutional review board of the University
f Michigan.
riteria for retinopathy and nephropathy. Retinopathy
as graded by stereoscopic color photographs using the
arly Treatment of Diabetic Retinopathy Scale (EDTRS)
19). The DC subjects were without retinopathy (level 10).
evel 20 of the EDTRS was divided into two subgroups:
evel 20a, with 1 and 3 microaneurysms, and level 20b,
ith 3 microaneurysms. The DMA subjects were de-
Abbreviations and Acronyms
C  controls
CAN  cardiovascular autonomic neuropathy
CPT  cold pressor testing
CRP  C-reactive peptide
DC  diabetic control subjects
DMA  early microangiopathy
LV  left ventricle/ventricular
MBF  myocardial blood flow
PET  positron emission tomography
vWF  von Willebrand factor
([11C]HED)  [11C]meta-hydroxyephedrine
able 1. Clinical Details
C
(n  10)
DC
(n  12)
DMA
(n  16)
ale:female 6:4 7:5 11:5
ge (yrs) 38  8 43  9 41  10
iabetes duration (yrs) — 28 7 21  11
b A1c 4.8  0.2 7.8  1.1* 7.8 1.3*
rinary microalbuminuria
(30 mg/24 h) (/)
N/D 12/0 14/2
NSI questionnaire (/) N/D 12/0 6/10
NSI examination (/) N/D 12/0 16/0
etinopathy (level 10/levels
20b–35/proliferative)
N/D 12/—/— —/16/—
otal cholesterol (mg/dl) 191  59 191  43 165 34
DLc (mg/dl) 107  48 120  43 90 27
DLc (mg/dl) 57 16 53  20 54  19
riglycerides (mg/dl) 119  74 94  62 110  52
ata shown as mean values  SD. *p  0.05 vs. C.
C controls; DC diabetic control subjects; DMA early microangiography;
b  hemoglobin; HDLC  high-density lipoprotein cholesterol; LDLC i
ow-density lipoprotein cholesterol; MNSI  Michigan Neuropathy Screening
nstrument; N/D  not done.ned by level 20b to 35 retinopathy or microalbuminuria
20).
RITERIA FOR NEUROPATHY. Subjects were classified for
europathy based on the results of cardiovascular autonomic
unction testing (21) (Table 2) and the Michigan Neurop-
thy Screening Instrument (MNSI) examination score (22).
he DC subjects had no evidence of neuropathy; DMA
ad no or minimal evidence of neuropathy (2 abnormal
AN reflex tests, normal MNSI examination score, normal
r abnormal MNSI symptom score).
ositron emission tomography (PET) studies. Cardiac
ET imaging was performed with a whole-body PET
canner (Siemens ECAT/931, Siemens/ECAT Exact, or
iemens/ECAT Exact HR, Siemens Medical Solutions,
alvern, Pennsylvania). There were three separate PET
maging sessions. The first session used [11C]meta-
ydroxyephedrine ([11C]HED) to evaluate the integrity of
ardiac sympathetic innervation. The second session used
13N]ammonia to measure MBF regulation in response to
old pressor stimulation. The third session used [13N]am-
onia to measure the MBF reserve in response to adenosine
nfusion. All PET scans for a given patient were performed
n the same scanner.
valuation of cardiac sympathetic innervation with
11C]HED. After the transmission scan, a 60-min dynamic
ET image acquisition sequence was started as 20 mCi of
11C]HED was injected over 30 s, as previously reported
8). After correction for attenuation, transaxial PET data
ere reoriented and re-sliced into short-axis view data sets
slice thickness 0.8 cm) for subsequent quantitative analyses.
Regional neuronal retention of [11C]HED was quantified
sing a “retention index” approach (8) that corrects for tracer
elivery. The heterogeneity of regional LV [11C]HED reten-
ion in each diabetic subject was compared with the normal
eference distribution by performing a z-score analysis. Sectors
hat had a z score 2.5 were defined as abnormal. The extent
f [11C]HED retention heterogeneity was expressed as the
ercentage of all sectors in the patient’s polar map that were
bnormal (i.e., had z scores 2.5).
valuation of regional MBF regulation with [13N]ammonia.
13N]ammonia studies at rest and during stress were per-
ormed sequentially in a single session. The resting perfu-
ion scan was started by initiating a 15-min dynamic PET
cquisition sequence as 20 mCi of [13N]ammonia was
able 2. Autonomic Neuropathy Details
C DC DMA
eart rate variability
(beats/min)
21  8 20  5 18  12
alsalva ratio 1.57  0.3 1.58  0.4 1.61  0.37
0/15 ratio 1.38  0.2 1.17  0.07 1.25  0.2
ystolic BP response to
standing (mm Hg)
12  5 2  6 3  7
ata shown as mean values  SD.
BP  blood pressure; other abbreviations as in Table 1.ntravenously injected (9). After 50 min, a cold pressor stress
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Sympathetic Dysfunction in Diabetes December 21, 2004:2368–7413N]ammonia study was performed with stimulation start-
ng 30 s before tracer injection. Blood pressure and heart
ate were recorded at 1-min intervals. For the adenosine
tudy, adenosine was infused intravenously over 6 min at
40 g/kg/min to achieve maximal coronary vasodilatation
9). At 3 min, 20 mCi [13N]ammonia was injected over 30 s
nd imaged for 3 to 18 min. Blood pressure and heart rate
ere measured every minute during adenosine infusion and
hen at 10 and 18 min. Pressure-rate product was calculated
s heart rate times systolic blood pressure divided by 100.
Regional MBF was estimated from the measured [13N]am-
onia kinetics (23) as previously reported (9). Regional MBF
eserve values were estimated by dividing the stress flow value
y the resting flow value. Mean values of resting flow, stress
ow, and MBF reserve were then determined for the same LV
egions used in the [11C]HED analysis.
old pressor testing (CPT). The CPT to provoke sym-
athetic activation was performed by applying a bag filled
ith ice chips to the forehead for 2 min (24).
chocardiography. Two-dimensional echocardiography
nd pulsed tissue Doppler parameters were used to
lassify diastolic function (25). Data acquired included
he ratio of peak flow velocities during early filling and
trial contraction (E/A ratio), Doppler tissue imaging of
he mitral annulus early diastolic velocity (Ea), the mitral
nnular motion with atrial contraction (Aa), and the
oppler tissue imaging of the mitral annulus (Ea/Aa
atio). Left ventricular diastolic dysfunction was defined
y an E/A ratio 1, or if 1, by an Ea/Aa ratio 1. Left
entricular mass was determined by the formula LV mass
0.8  1.05  (S  P  LVEDD)3  (LVEDD)3,
here S  LV septal thickness, P  LV posterior wall
hickness, and LVEDD  LV end-diastolic diameter.
he LV mass index was then determined (LV mass/body
urface area). Abnormal LV mass index was defined by
alues 100 g/m2 in women and 131 g/m2 in men.
xidative stress measurements. Urine F2 isoprostanes
ere measured by enzyme-linked immunosorbent assay.
lasma total radical-trapping antioxidant parameter was
easured as previously reported (26).
tatistical analysis. Statistical analysis was performed
sing Super ANOVA (Abacus Concepts Inc., Berkeley,
alifornia). The equality of experimental group means was
ested by a one-way analysis of variance and, if significant,
he differences were assessed by the Student-Newman-
euls multiple-range test. If the variances for the variables
iffered significantly, logarithmic transformation was per-
ormed. All analyses were then performed on the trans-
ormed data. The significance of changes in measurements
rom baseline was determined using a paired t test. Signif-
cance was defined at the 0.05 level.
ESULTS
lycemic control was equivalent in diabetic subjects (Table 1).
he urine microalbumin/creatinine ratio was not significantly (ifferent between DC and DMA subjects. Plasma lipid levels
id not differ between groups. Ten DMA subjects either had
ymptoms consistent with peripheral neuropathy or one ab-
ormal CAN reflect test (Table 2). However, none had an
bnormal MNSI examination score.
MA subjects demonstrate defects of LV[11C]HED
etention. Deficits of distal LV [11C]HED retention af-
ected1% of the LV (Fig. 1A) in DC subjects, but affected
36% of the LV in DMA subjects despite normal
ardiovascular reflex testing. Unlike the small distal deficits
f LV [11C]HED retention identified in DC subjects,
eficits of tracer retention in DMA subjects were more
lobal, affecting both the basal as well as the distal segments
igure 1. (A) Extent of left ventricular (LV) [11C]meta-hydroxyephedrine
[11C]HED) retention deficits in different subject groups. Normalized
11C]HED retention data are displayed as polar coordinate maps of relative
racer activity ([11C]/[13N]). The “extent” of the heterogeneity is expressed
s the percentage of sectors in the polar map that are abnormal, i.e.,
i 2.5. p  0.01 early microangiopathy (DMA) versus diabetic control
ubjects (DC). Horizontal bars  mean value. (B) Left ventricular
11C]HED retention is globally decreased in a DMA subject. Quanti-
ative assessment of LV [11C]HED retention (expressed as a retention
ndex [RI]) demonstrated reduced retention in all LV sectors in a DMA
ubject (open plot) compared with the values obtained in nondiabetic
ontrol subjects (shaded plot).Fig. 1B).
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December 21, 2004:2368–74 Sympathetic Dysfunction in Diabeteslasma norepinephrine excursions are exaggerated on
PTin DMA subjects. Resting heart rate and systolic
lood pressure were higher in the diabetic subjects com-
ared with controls (Table 3). Basal levels of plasma
orepinephrine tended to be lower in all the diabetic
ubjects. On CPT, the change in norepinephrine levels was
2-fold greater in DMA subjects than in the C and DC
ubjects (p  0.05). No significant differences in resting or
tress epinephrine levels were detected between groups (data
ot shown).
PT results in paradoxical LV vasoconstriction in
MA subjects. In response to sympathetic activation,
lobal MBF reserve was preserved in DC subjects and
educed by 35% (p  0.05) in DMA subjects (Table 4).
egionally, in the basal myocardial segments, MBF reserve
as preserved in DC subjects but very abnormal (a para-
oxical 12% [p  0.05] reduction of myocardial perfusion)
n DMA subjects. Myocardial blood flow reserve in the
istal myocardial segments paralleled global perfusion mea-
urements, and reduced perfusion was not observed in
MA subjects.
ssessment for occult regional myocardial perfusion
efects. Regional discrete perfusion defects were sought by
isual and semiquantitative analysis of MBF at rest and
uring adenosine stress. Visual inspection of standardized
olor-coded blood flow images taken from the distal and
able 3. Heart Rate, BP, and Norepinephrine Response to CPT
C DC DMA
eart rate, rest
(beats/min)
56  9 68  10* 74  16*
eart rate, stress
(beats/min)
67  12 79  13 86  15*
eart rate, delta
(beats/min)
11  7 13  5 13  7
ystolic BP, rest
(mm Hg)
99  17 121  12* 128 12*
ystolic BP, stress
(mm Hg)
124  30 154  27 152  17
ystolic BP, delta
(mm Hg)
26  15 29  17 24  14
orepinephrine, rest
(pg/ml)
312  168 242  96 228  66
orepinephrine, stress
(pg/ml)
451  245† 378  89† 518 200†
orepinephrine, delta
(pg/ml)
138  37 135  25 290  85*
ata shown as mean value  SD. *p  0.05 vs. C. †p  0.05 vs. baseline.
CPT  cold pressor testing; other abbreviation as in Tables 1 and 2.
able 4. LV MBF Reserve on CPT
Myocardial Region C DC DMA
asal anterior 1.45 0.59 1.51 0.3 0.88 0.22*
istal inferolateral 1.6  0.62 1.7 0.4 0.99 0.41*
lobal 1.5 0.49 1.47 0.18 0.98 0.15*
ata shown as mean values  SD. *p  0.05 vs. C and DC.t
CPT cold pressor testing; LV left ventricular; MBFmyocardial blood flow;
ther abbreviations as in Table 1.asal short axis and the vertical and horizontal long axis
onfirmed homogeneous [13N]ammonia retention.
ystemic hemodynamic responses to adenosine infusi-
n. No differences were observed in the hemodynamic
esponse to adenosine infusion among the subject groups.
he resting and adenosine stress pressure-rate products
ere similar in the C and diabetic subjects (data not shown).
BF reserve during adenosine stimulation is reduced in
MA subjects. Compared with C subjects (69  9
l/min/g of tissue), resting MBF was elevated in both the DC
85 20 ml/100 g/min) and DMA (91 13 ml/100 g/min)
ubjects (p 0.05). During adenosine infusion, the increase in
V MBF was blunted in the DMA (204  42 ml/100
/min) compared with the DC (267 126 ml/100 g/min) and
(275 26 ml/100 g/min) subjects (p 0.2). Finally, MBF
eserve differed between groups (p 0.01). Compared with C
ubjects, MBF reserve was reduced by 21% (p  0.05) and
5% (p  0.01) in the DC and DMA subjects, respectively
Fig. 2). The difference between DC and DMA subjects was
lso statistically significant (p  0.05). In contrast to our
reviously reported findings in subjects with advanced CAN
9), LV MBF reserve did not differ regionally (data not
hown).
ffect of diabetes and microangiopathy on von Wille-
rand factor (vWF) antigen, C-reactive peptide (CRP),
nd oxidative stress. Compared with C subjects (107 
0%), vWF antigen increased by 67% (p 0.01) in DMA
ubjects (179  54%) but was unchanged in DC subjects
115  10%). In comparison with C subjects (0.05  0.03
g/dl), CRP levels increased by 1.8-fold (p  0.4) and
.2-fold (p  0.05) in DC (0.09  0.05 mg/dl) and
MA subjects (0.21  0.2 mg/dl), respectively. Plasma
igure 2. Change in global myocardial blood flow reserve (MBFR) in
esponse to adenosine infusion. [13N]ammonia positron emission tomog-
aphy was used to explore MBF regulation in response to adenosine. p 
.05 diabetic control subjects (DC) versus controls (C). p  0.05 early
icroangiopathy (DMA) versus C and DC. Horizontal bars  mean
alue.otal radical-trapping antioxidant parameter was decreased
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Sympathetic Dysfunction in Diabetes December 21, 2004:2368–74n all diabetic subjects (1,028  44 M, 754  126 M,
nd 547  52 M, in C, DC, and DMA, respectively),
ith the difference between DMA and C subjects achiev-
ng statistical significance (p  0.01). Compared with C
ubjects (99  21 pg/mmol creatinine), urine 8-epi prosta-
landin F2-alpha increased three-fold (278  34 pg/mmol
reatinine) (p  0.4) and 11-fold (1,047  247 pg/mmol
reatinine) (p  0.01) in DC and DMA subjects,
espectively.
MA subjects demonstrate LV diastolic dysfunc-
ion. Left ventricular function was assessed in consecutively
ecruited DMA (n  8, mean age 50  7 years, 5 men
nd 3 women) and DC (n  8, mean age 44  8 years, 4
en and 4 women) subjects who were within one year of
ompletion of the other studies reported herein. No subject
ad abnormal systolic function. Six DMA subjects, but
one of the DC subjects, exhibited diastolic dysfunction
Table 5). Three DMA subjects had an abnormal LV
ass index, which was normal in all DC subjects.
ISCUSSION
he aim of this study was to explore the potential
echanisms linked to the development of enhanced
ardiac risk in diabetes. Compared with healthy controls,
iabetic subjects with early subclinical microangiopathy
emonstrated extensive deficits of LV [11C]HED reten-
ion, exaggerated plasma norepinephrine excursions, im-
aired MBF regulation, and LV diastolic dysfunction.
herefore, we propose that in diabetes, augmented car-
iac sympathetic tone and responsiveness in concert with
mpaired perfusion may contribute to the eventual devel-
pment of myocardial injury.
The extensive global deficits of [11C]HED retention
bserved in DMA subjects despite good glycemic control
iffer markedly from previous findings in metabolically
table (8) or metabolically compromised (27) type 1 diabetic
ubjects, and they suggest an etiology other than neuronal
oss or acute hyperglycemia-induced neuronal dysfunction.
oreover, these findings differ markedly from our previous
ndings in subjects with either early (28) or more severe
8,9) CAN (accompanied by abnormal CAN reflex tests), in
able 5. LV Diastolic Function
DC
(n  8)
DMA
(n  8)
p
Value
-wave peak velocity (cm/s) 87 19 74  15 0.2
-wave peak velocity (cm/s) 70 20 80  21 0.4
/A ratio 1.27  0.14 0.96  0.21 0.008
a-wave peak velocity (cm/s) 26 10 18  5 0.09
a wave peak velocity (cm/s) 21  8 23  8 0.6
a/Aa ratio 1.25  0.3 0.88  0.3 0.06
V mass index (g/m2) 80  13 100  32 0.2
ata shown as mean values  SD.
A  peak velocity during atrial contraction; Aa  DTI of the mitral annulus with
trial contraction; E  peak velocity during early LV filling; Ea  DTI of the mitral
nnulus early diastolic velocity; LV  left ventricular; other abbreviations as in Table 1.hom deficits of [11C]HED retention begin distally and chen spread proximally and circumferentially, eventually
esulting in islands of basal increased [11C]HED retention
8,9,28).
Sympathetic neurotransmitter analogues such as [11C]HED
ndergo highly specific and rapid uptake into sympathetic
erve varicosities via norepinephrine transporters (“uptake-
”) (29). In the isolated rat heart elevated norepinephrine
erfusion concentrations increase neuronal HED clearance
ates, suggesting that neuronal “recycling” of HED is impaired
y high synaptic norepinephrine levels (29). In the acute
ix-week diabetic rat heart, retention of LV [11C]HED is
nversely related to increased cardiac norepinephrine levels
16), which precedes cardiac small nerve fiber loss (M.J.
tevens, personal observations, 1999). Moreover, an inverse
elationship of myocardial retention of metaiodobenzyl
uanidine to plasma catecholamines occurs in subjects with
heochromocytoma (30), which is thought to reflect com-
etition for uptake into neuronal storage vesicles (31).
hese data implicate increased synaptic norepinephrine as
he most likely explanation for the reduction of cardiac
11C]HED retention in DMA subjects. Direct measure-
ent of cardiac norepinephrine spillover is, however, re-
uired to confirm the potential mechanism(s) of this defect.
In DMA subjects, systemic plasma norepinephrine
xcursions in response to CPT were exaggerated, consistent
ith enhanced cardiovascular sympathetic nervous system
eactivity. The unchanged resting systemic plasma norepi-
ephrine levels do not preclude an increase of basal cardiac
drenergic tone, as a similar disassociation has been identi-
ed in arrhythmogenic right ventricular cardiomyopathy,
hich is characterized by increased cardiac, but not sys-
emic, sympathetic nerve activity (32). Although the mech-
nisms of increased norepinephrine responses in DMA
ubjects are unknown, depletion of nitric oxide (and hence
ysinhibition) in sympathetic ganglia (33) and/or vascular
ndothelium (34) or vascular denervation (35) have been
roposed. It is unclear as to whether cardiac norepinephrine
esponsiveness was increased in parallel. More detailed
etermination of systemic and regional norepinephrine
inetics in DMA subjects is required to confirm and
xtend these observations.
In DMA subjects, increased adrenergic reactivity was
ssociated with increased oxidative stress, elevated CRP
nd plasma vWF antigen, and impaired MBF reserve,
onsistent with endothelial dysfunction. On CPT, how-
ver, the most abnormal blood flow responses were
bserved in the basal myocardial segments. Diabetes-
nduced endothelial dysfunction is expected to be global
n the LV, suggesting that other factors such as variations
n the density of LV sympathetic innervation may have
ontributed (16). These findings are consistent with our
arlier identification of maximal impairment of MBF
eserve in the innervated basal myocardium of diabetic
ubjects with advanced CAN (9). On sympathetic acti-
ation, augmented accumulation of norepinephrine, in-
reased oxidative stress, and apoptosis (36) may have
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December 21, 2004:2368–74 Sympathetic Dysfunction in Diabetesontributed to abnormal vascular reactivity. Paradoxic
asoconstriction responses (10,11,37) complicate coro-
ary atherosclerosis. Our studies indicate that paradoxic
oronary vasoconstriction can occur in type 1 diabetes in
he absence of atheroma. (Alternatively, however, we
annot exclude the less likely possibility that globally
mpaired cardiac sympathetic function was principally the
ause of the blunted MBF response.)
On adenosine infusion, global MBF reserve was re-
uced in DMA subjects to an extent that exceeded that
bserved in the DC subjects. Reduced MBF reserve has
een reported in subjects with type 2 diabetes (11,12) as
ell as type 1 diabetes (9,12–14) and has been associated
ith impaired glucose control (38) or cardiovascular
ympathetic denervation (9,14). We have now demon-
trated that neither impairment of metabolic control nor
he presence of cardiovascular denervation is a prerequi-
ite for the development of impaired vasodilatory reserve.
lthough the mechanism(s) of this deficit is unknown,
ndothelial dysfunction, in concert with decreased myo-
ardial vascularity (9,39), may be an important contrib-
ting factor.
In diabetes, a putative cardiomyopathy comprising
yocardial interstitial and perivascular fibrosis (1) and
poptosis (2) has been linked to impaired LV function
3). Our preliminary studies identified diastolic dysfunc-
ion in five of eight consecutively recruited DMA
ubjects but none of the healthy DC subjects. Although
he precise pathogenetic mechanisms are unclear, alter-
tions of sympathetic tone could contribute to myocardial
amage. For example, increased cardiac sympathetic tone
ay decrease myocardial vascularity (39), stimulate vas-
ular hyperreactivity (40), increase mitochondrial reactive
xygen species production (17), perturb intracellular
ignaling (41), precipitate myocardial apoptosis (2,41),
nd promote myocardial remodeling (42). Therefore, in
he course of the development of the microvascular
omplications of diabetes, elevated cardiac sympathetic
one may play a key pathogenetic role in the subsequent
evelopment of myocardial injury and dysfunction.
onclusions. In summary, subjects with stable type 1
iabetes and preclinical microangiopathy demonstrate wide-
anging abnormalities of cardiac sympathetic innervation
nd blood flow regulation, which may contribute to the
ubsequent development of myocardial injury. Limitations
f our study include the relatively small subject number as
ell as the cross-sectional design, which, although it pro-
ides provocative new findings, does not directly address the
ole of these pathophysiologic changes in the development
f impaired myocardial function. Future larger, prospective
tudies are needed to confirm these preliminary observa-
ions. Direct confirmation of the findings presented herein
ay form the rationale for the development of prophylactic
reatment strategies aimed at reducing cardiac risk in
iabetes.
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